

Ono M, Ishikawa M, Kimura H, Hayashi S, Matsumura K, Watanabe H, Shimizu Y, Cheng Y, Cui M, Kawashima H, Saji H.	Development of dual functional SPECT/fluorescent probes for imaging cerebral β -amyloid plaques.	Bioorganic & Medicinal Chemistry Letters	20	3885-3888	2010
Watanabe H, Ono M, Haratake M, Kobashi N, Saji H, Nakayama M.	Synthesis and characterization of novel phenylindoles as potential probes for imaging of β -amyloid plaques in the brain.	Bioorganic & Medicinal Chemistry	18	4740-4746	2010
Ono M, Ikeoka R, Watanabe H, Kimura H, Fuchigami T, Haratake M, Saji H, Nakayama M.	Synthesis and evaluation of novel chalcone derivatives with $^{99m}\text{Tc}/\text{Re}$ complexes as potential probes for detection of β -amyloid plaques.	ACS Chemical Neuroscience	1	598-607	2010
Cheng Y, Ono M, Kimura H, Kagawa S, Nishii R, Kawashima H, Saji H.	Fluorinated benzofuran derivatives for PET imaging of β -amyloid plaques in Alzheimer's disease brains.	ACS Medicinal Chemistry Letters	1	321-325	2010
Ono M, Ikeoka R, Watanabe H, Kimura H, Fuchigami T, Haratake M, Saji H, Nakayama M.	$^{99m}\text{Tc}/\text{Re}$ complexes based on flavone and aurone as SPECT probes for imaging cerebral β -amyloid plaques.	Bioorganic & Medicinal Chemistry Letters	20	5742-5748	2010
Ono M, Fuchi Y, Fuchigami T, Kobashi N, Kimura H, Haratake M, Saji H, Nakayama M.	Novel benzofurans with ^{99m}Tc complexes as probes for imaging cerebral β -amyloid plaques using single photon emission computed tomography.	ACS Medicinal Chemistry Letters	1	443-447	2010
Cheng Y, Ono M, Kimura H, Kagawa S, Nishii R, Saji H.	A novel ^{18}F -labeled pyridyl benzofuran derivative for imaging of β -amyloid plaques in Alzheimer's brains.	Bioorganic & Medicinal Chemistry Letters	20	6141-6144	2010
Temma T, Ogawa Y, Kuge Y, Ishino S, Takai N, Nishigori K, Shiomi M, Ono M, Saji H.	Tissue factor detection for selectively discriminating unstable plaques in an atherosclerotic rabbit model.	J Nucl Med	51	1979-1986	2010
Sano K, Temma T, Kuge Y, Kudo T, Kamihashi J, Zhao S, Saji H.	Radioimmunodetection of membrane type-1 matrix metalloproteinase relevant to tumor malignancy with a pre-targeting method.	Biol Pharm Bull	33	1589-1595	2010

Kuge Y, Takai N, Ogawa Y, Temma T, Zhao Y, Nishigori K, Ishino S, Kamihashi J, Kiyono Y, Shiomi M, Saji H.	Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques.	Eur J Nucl Med Mol Imaging	37	2093-2104	2010
Ueda M, Iida Y, Yoneyama T, Kawai T, Ogawa M, Magata Y, Saji H.	In vivo relationship between thalamic nicotinic acetylcholine receptor occupancy rates and antiallodynic effects in a rat model of neuropathic pain: persistent agonist binding inhibits the expression of antiallodynic effects.	Synapse	65	77-83	2011
Masuda R, Oishi S, Ohno H, Kimura H, Saji H, Fujii N.	Concise Site-specific DTPA Labeling of Peptides: Application to Peptide Probes for the Chemokine Receptor CXCR4.	Bioorganic & Medicinal Chemistry	19	3216-3220	2011
上田真史、天満敬、佐治英郎.	悪性腫瘍の分子イメージングのための新しい分子プローブの設計.	PET journal	12	32-34	2010
Ko AC, Ridsdale A, Smith MS, Mostaco-Guidolin LB, Hewko MD, Pegoraro AF, Kohlenberg EK, Schattka B, Shiomi M, Stolow A, Sowa MG	Multimodal nonlinear optical imaging of atherosclerotic plaque development in myocardial infarction-prone rabbits.	J Biomed Opt	15(2)	020501-3	2010
Yoshida M, Masunaga K, Nagata T, Satoji Y, Shiomi M	The effects of chronic hyperlipidemia on bladder function in myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits.	Neurorol Urolyn	29(7)	1350-4	2010
Nitta-Seko A, Nitta N, Shiomi M, Sonoda A, Ota S, Tsuchiya K, Takahashi M, Fujimiya M, Murata K	Utility of contrast-enhanced ultrasonography for qualitative imaging of atherosclerosis in Watanabe heritable hyperlipidemic rabbits: initial experimental study.	Jpn J Radiol	28(9)	656-62	2010
Mostaco-Guidolin LB, Sowa MG, Ridsdale A, Pegoraro AF, Smith MS, Hewko MD, Kohlenberg EK, Schattka B, Shiomi M, Stolow A, Ko AC	Differentiating atherosclerotic plaque burden in arterial tissues using femtosecond CARS-based multimodal nonlinear optical imaging.	JBiomed Opt Express	1(1)	59-73	2010

Ono M, Hayashi S, Matsumura K, Kimura H, Okamoto Y, Ihara M, Takahashi R, Mori H, Saji H.	Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains.	ACS Chemical Neuroscience	2	269-275	2011
Matsumura K, Ono M, Hayashi S, Kimura H, Okamoto Y, Ihara M, Takahashi R, Mori H, Saji H.	Phenyldiazenyl benzothiazole derivatives as probes for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains.	Medicinal Chemistry Communications	2	596-600	2011
Harada N, Kimura H, Ono M, Mori D, Ohmomo Y, Kajimoto T, Kawashima H, Saji H.	Effective synthesis of ^{99m} Tc tricarbonyl complexes by microwave heating.	Journal of Organometallic Chemistry	696	3745-3749	2011
Arimitsu K, Kajimoto T, Kimura H, Ono M, Ozeki M, Node M, Ohmomo Y, Saji H, Yamashita M.	Alternative synthesis of radioiodinated trisaccharide derivatives, 2-(4- ¹²⁵ Iodophenyl)ethyl 2-acetamido-2-deoxy-β-d-glucopyranosyl-(1→2)-α-d-mannopyranosyl-(1→6)-β-d-glucopyranoside, and preparation of its analogs having different lengths of alkyl chains instead of ethyl group: Acceptor substrates of n-acetylglucosaminyltransferase v for in vivo imaging.	Heterocycles	83	2779-2802	2011
Ogawa K, Saji H.	Advances in drug design of radiometal-based imaging agents for bone disorders.	Int J Mol Imaging.	53	7687	2011
Watanabe H, Ono M, Kimura H, Kagawa S, Nishii R, Fuchigami T, Haratake M, Nakayama M, Saji H.	A dual fluorinated and iodinated radiotracer for PET and SPECT imaging of β-amyloid plaques in the brain.	Bioorg Med Chem Lett.	21(21)	6519-22	2011
Ueda M, Kudo T, Mutou Y, Umeda IO, Miyano A, Ogawa K, Ono M, Fujii H, Kizaka-Kondoh S, Hiraoka M, Saji H.	Evaluation of [¹²⁵ I]IPOS as a molecular imaging probe for hypoxia-inducible factor-1-active regions in a tumor: comparison among single-photon emission computed tomography/X-ray computed tomography imaging, autoradiography, and immunohistochemistry.	Cancer Sci.	102(11)	2090-6	2011
Shimizu Y, Temma T, Sano K, Ono M, Saji H.	Development of membrane type-1 matrix metalloproteinase-specific activatable fluorescent probe for malignant tumor detection.	Cancer Sci.	102(10)	1897-903	2011

Mukai T, Hagimori M, Arimitsu K, Katoh T, Ukon M, Kajimoto T, Kimura H, Magata Y, Miyoshi E, Taniguchi N, Node M, Saji H.	Synthesis and evaluation of a radioiodinated trisaccharide derivative as a synthetic substrate for a sensitive N-acetylglucosaminyltransferase V radioassay.	Bioorg Med Chem.	19(14)	4312-21	2011
Cui M, Ono M, Kimura H, Liu B, Saji H.	Novel quinoxaline derivatives for in vivo imaging of β -amyloid plaques in the brain.	Bioorg Med Chem Lett.	21(14)	4193-6	2011
Cui M, Ono M, Kimura H, Liu B, Saji H.	Synthesis and evaluation of benzofuran-2-yl(phenyl)methanone derivatives as ligands for β -amyloid plaques.	Bioorg Med Chem.	19(13)	4148-53	2011
Ono M, Saji H.	SPECT Imaging Agents for Detecting Cerebral β -Amyloid Plaques.	Int J Mol Imaging.	67	5432	2011
Masuda R, Oishi S, Ohno H, Kimura H, Saji H, Fujii N.	Concise site-specific synthesis of DTPA-peptide conjugates: application to imaging probes for the chemokine receptor CXCR4.	Bioorg Med Chem.	19(10)	3216-20	2011
Cui M, Ono M, Kimura H, Kawashima H, Liu BL, Saji H.	Radioiodinated benzimidazole derivatives as single photon emission computed tomography probes for imaging of β -amyloid plaques in Alzheimer's disease.	Nucl Med Biol.	38(3)	313-20	2011
Hirata K, Kuge Y, Yokota C, Harada A, Kokame K, Inoue H, Kawashima H, Hanzawa H, Shono Y, Saji H, Minematsu K, Tamaki N.	Gene and protein analysis of brain derived neurotrophic factor expression in relation to neurological recovery induced by an enriched environment in a rat stroke model.	Neurosci Lett.	495(3)	210-5	2011
Ono M, Cheng Y, Kimura H, Cui M, Kagawa S, Nishii R, Saji H.	Novel ^{18}F -labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of β -amyloid plaques in Alzheimer's brains.	J Med Chem.	54(8)	2971-9	2011
Cui M, Ono M, Kimura H, Liu B, Saji H.	Synthesis and structure-affinity relationships of novel dibenzylideneacetone derivatives as probes for β -amyloid plaques.	J Med Chem.	54(7)	2225-40	2011
Makino A, Harada H, Okada T, Kimura H, Amano H, Saji H, Hiraoka M, Kimura S.	Effective encapsulation of a new cationic gadolinium chelate into apoferritin and its evaluation as an MRI contrast agent.	Nanomedicine.	7(5)	638-46	2011
Sano K, Temma T, Azuma T, Nakai R, Narazaki M, Kuge Y, Saji H.	A pre-targeting strategy for MR imaging of functional molecules using dendritic Gd-based contrast agents.	Mol Imaging Biol.	13(6)	1196-203	2011
Shimizu S, Atsumi R, Nakazawa T, Izumi T, Sudo K, Okazaki O, Saji H.	Ticlopidine-induced hepatotoxicity in a GSH-depleted rat model.	Arch Toxicol.	85(4)	347-53	2011

Kudo T, Ueda M, Konishi H, Kawashima H, Kuge Y, Mukai T, Miyano A, Tanaka S, Kizaka-Kondoh S, Hiraoka M, Saji H.	PET imaging of hypoxia-inducible factor-1-active tumor cells with pretargeted oxygen-dependent degradable streptavidin and a novel ¹⁸ F-labeled biotin derivative.	Mol Imaging Biol.	13(5)	1003-10	2011
Iwata A, Miura S, Zhang B, Imaizumi S, Uehara Y, Shiomi M, Saku K.	Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits.	Atherosclerosis.	218(2)	300-7	2011
Takahashi S, Ito T, Zenimaru Y, Suzuki J, Miyamori I, Takahashi M, Takahashi M, Ishida T, Ishida T, Hirata K, Yamamoto TT, Iwasaki T, Hattori H, Shiomi M.	Species differences of macrophage very low-density-lipoprotein (VLDL) receptor protein expression.	Biochem Biophys Res Commun.	407(4)	656-62	2011
Kobayashi T, Ito T, Shiomi M.	Roles of the WHHL rabbit in translational research on hypercholesterolemia and cardiovascular diseases.	J Biomed Biotechnol.	2011	406473	2011
Ono M, Ohgami M, Haratake M, Saji H, Nakayama M.	A novel bifunctional chelating agent based on bis(hydroxamamide) for ^{99m} Tc labeling of polypeptides.	Journal of Labelled Compounds and Radiopharmaceuticals	55	71-79	2012
Matsumura K, Ono M, Kimura H, Ueda M, Nakamoto Y, Togashi K, Okamoto Y, Ihara M, Takahashi R, Saji H.	¹⁸ F-Labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains.	ACS Medicinal Chemistry Letters	3	58-62	2012
Ono M, Watanabe H, Kimura H, Saji H.	BODIPY-based molecular probe for imaging of cerebral β -amyloid plaques.	ACS Chemical Neuroscience	3(4)	319-324	2012
Ono M, Saji H.	Molecular Approaches to the Treatment, Prophylaxis, and Diagnosis of Alzheimer's Disease: Novel PET/SPECT Imaging Probes for Diagnosis of Alzheimer's Disease.	J Pharmacol Sci.	118(3)	338-44	2012
Cheng Y, Ono M, Kimura H, Ueda M, Saji H.	Technetium-99m labeled pyridyl benzofuran derivatives as single photon emission computed tomography imaging probes for β -amyloid plaques in Alzheimer's brains.	J Med Chem.	55(5)	2279-86	2012
Nakase I, Konishi Y, Ueda M, Saji H, Futaki S.	Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo.	J Control Release.	159(2)	181-8	2012

Kimura H, Mori D, Harada N, Ono M, Ohmomo Y, Kajimoto T, Kawashima H, Saji H.	Microwave-assisted synthesis of organometallic complexes of $^{99m}\text{Tc}(\text{CO})_3$ and $\text{Re}(\text{CO})_3$: its application to radiopharmaceuticals.	Chem Pharm Bull (Tokyo).	60(1)	79-85	2012
Shimizu Y, Temma T, Hara I, Yamahara R, Ozeki E, Ono M, Saji H.	Development of novel nanocarrier-based near-infrared optical probes for in vivo tumor imaging.	J Fluoresc.	22(2)	719-27	2012
Shiomi M, Kobayashi T, Kuniyoshi N, Yamada S, Ito T.	WHHLMI rabbits with mesenteric fat accumulation are a novel animal model for metabolic syndrome.	Pathobiology.			2012 印刷中

Louis-Marie Houdebine
Jianglin Fan
Editors


Rabbit Biotechnology

*Rabbit Genomics, Transgenesis,
Cloning and Models*

神戸大学医学分館



0502009005390

 Springer

Chapter 7

Rabbit as a Model for the Study of Human Diseases

Masashi Shiomi

Abstract Although genetically modified mice are playing an essential role in the study of the expression and functions of individual genes, rabbits are useful animal models to extrapolate animal studies to humans. It is necessary that key gene expression and function are equivalent and close to human rather than the outward features or phenotype. For example, to study human hypercholesterolemia, the only hypercholesterolemia is insufficient, the lipoprotein profiles and enzymes in the lipoprotein metabolism of animal models are important for translational medicine. Lipoprotein metabolism of rabbits resembles humans closely. In addition, histopathological and/or immunohistochemical features of the tissues of disease similar to humans are important. In this field, spontaneous hypercholesterolemic rabbits (WHHL and WHHLM1 rabbits) have contributed to the elucidation of lipoprotein metabolism, atherogenesis, and to the development of therapeutic compounds, such as statins. Recently, a number of transgenic rabbits have been developed and they also contribute to the study of cardiac function and infectious diseases. Furthermore, rabbits are useful for studies of orthopedic surgery, cardiovascular surgery, and neoplastic diseases. Rabbit models have contributed not only to the mechanistic studies of human diseases but also to the development of therapeutic compounds, devices, or techniques for therapeutics. Applying these animal models in translational researches promotes the elucidations of human diseases.

Keywords animal models for human diseases, translational research, transgenic rabbits, WHHL/WHHLM1 rabbits

7.1 Introduction

After the genomes of human and mouse were fully deciphered, it has been recognized that the analyses of gene expression and functions are important to understand the pathogenesis and the mechanisms of diseases. It is critical for researchers to choose

M. Shiomi (✉)
Institute for Experimental Animals, Kobe University School of Medicine, 7-5-1,
Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
e-mail: icakusm@med.kobe-u.ac.jp

L.-M. Houdebine and J. Fan (eds.), *Rabbit Biotechnology: Rabbit Genomics, Transgenesis, Cloning and Models*,
© Springer Science + Business Media B.V. 2009

49

defect in LDL receptors which is characterized by the deletion of 12 base pairs of nucleotide in the LDL receptor gene (Yamamoto et al. 1986), which explained why there was marked accumulation of LDL in the plasma of WHHL rabbits (Tanzawa et al. 1980; Kita et al. 1981). In addition, WHHL rabbits, had tenfold higher levels of plasma triglycerides than normal rabbits. The CETP activity was high in the plasma (Son and Zilversmit 1986) and expression of apoB-editing enzyme was not detected in liver (Kozarsky et al. 1996). Therefore, lipoprotein metabolism of WHHL rabbits resembles that of human familial hypercholesterolemia patients. Because of these features, WHHL rabbits contributed to studies aiming at elucidating human lipoprotein metabolism, especially the LDL receptor pathway (Goldstein et al. 1983). In addition, WHHL rabbits have been used to screen the lipid-lowering effects of many compounds (Table 7.2). The best example of these studies examined in WHHL rabbits is statin (Watanabe et al. 1981; Tsujita 1986; Watanabe et al. 1988; Shiomi et al. 1995, 2005; Shiomi and Ito 1999a), which is one of the most effective hypocholesterolemic drugs prescribed right now for more than 30 million patients in the world each year.

WHHL rabbits have also contributed to studies of atherosclerosis and examination of anti-atherosclerotic effects of several compounds (Table 7.2). Due to the LDL receptor deficiency and hypercholesterolemia, atherosclerotic lesions developed spontaneously in WHHL rabbits under a normal standard chow. Therefore, WHHL rabbits can be used for the study of atherosclerosis initiation and the characterization of atherosclerotic pathology (Shiomi 2008). Atherosclerotic lesions of the aorta of WHHL rabbits were fatty streak at weaning, became macrophage-rich lesions at young age, established lesion (fibro-atheroma) at mature age, and complicated lesions (accumulation extracellular lipids, thin fibrous cap, calcification, and intra-

Table 7.2 Hypolipidemic and anti-atherosclerotic studies using WHHL or WHHLMI rabbits

Compounds	Hyperlipidemia	Aortic lesion	Coronary lesion
Statin	○	×, ○	○
Resin	○	○	n.d.
Statin + Resin	○	○	○
Squalene synthase inhibitor	○	○	○
MTP inhibitor	○	n.d.	n.d.
ACAT inhibitor	×, ○	×, ○	×, ○
Probucol	○	○	n.d.
M-CSF or GM-CSF	○	○	n.d.
ApoE	○	○	n.d.
Fibrate	×	n.d.	n.d.
Fish oil	×, ○	×, ○	n.d.
Thiazolidinedione	×	Δ	Δ
Ca ²⁺ antagonist	×	×	×
β-blocker	×	×	×
ACE inhibitor	×	○	n.d.
A-II receptor antagonist	×	○	n.d.
Gene therapy	○	n.d.	n.d.

○, effective; ×, not effective; n.d., not determined


plaque hemorrhage) at old age. These histological features resemble many respects of human atherosclerotic lesions. Using WHHL rabbits, Watanabe et al. demonstrated that plasma cholesterol reduction by pravastatin, an inhibitor of cholesterol synthesis, can delay development of atherosclerosis (Watanabe et al. 1988).

7.3.2 WHHLMi Rabbits

Although atherosclerotic lesions developed in aorta of every WHHL rabbit, the incidence of coronary atherosclerosis was very low and myocardial infarction did not occur. To develop coronary atherosclerosis in WHHL rabbits, Watanabe et al. (Watanabe et al. 1985) started to develop coronary atherosclerosis-prone WHHL rabbits by selective breeding in 1995. Studies using the coronary atherosclerosis-prone WHHL rabbits demonstrated that reduction of plasma cholesterol levels by statins improved composition of coronary plaques from unstable lesions to stable lesions (Shiomi et al. 1995, 2005; Shiomi and Ito 1999a). However, the incidence of myocardial infarction was still very low due to macrophage-poor lesions. In quantitative analyses of atherosclerotic lesions using imaging techniques (Shiomi et al. 1994), the composition of coronary atherosclerosis differed from the aortic ones. Thereafter, Shiomi et al. (Shiomi et al. 2003) started selective breeding from 1993 using indices of macrophage-rich coronary lesions, severe coronary stenosis, higher plasma cholesterol levels, and development of myocardial infarction. Seven years after, the incidence and severity of coronary lesions increased. The cumulated incidence of myocardial infarction in 30 months old animals was increased from 23% of the original WHHL rabbits to 97% in WHHLMi rabbits by the selective breeding (Shiomi et al. 2003). The degree of coronary stenosis (cross-sectional narrowing) at the age of 10–14 months also increased from 38% in the original WHHL rabbits to 82% in the WHHLMi rabbits (Ito et al. 2004). Myocardial infarction of WHHLMi rabbits is classified into four types: subendocardial infarction, intramural infarction, transmural infarction, and subepicardial infarction. In WHHLMi rabbits, fresh myocardial lesions consisted of hyperemia, eosinophilic degeneration of myocardial cells and infiltration of inflammatory cells was observed in the vicinity of old myocardial lesions consisting of myocardial fibrosis, scar, and dissolution of myocardial cells. The electrocardiograms from a WHHLMi rabbit monitored immediately before sudden decease showed an elevation of ST-segment and deep Q-wave which are the typical changes of acute myocardial infarction in humans. The coronary lesions of WHHLMi rabbits show various types, vulnerable plaque (large lipid core covered with thin fibrous cap), macrophage-rich plaque, complicated plaque and fibrous plaque, all similar to human coronary plaques. However, rupture of coronary plaque and/or formation of thrombosis were not observed. The next theme is the development of acute coronary syndrome in WHHLMi rabbits, with the coronary plaque rupture and the generation of thrombosis.

Figure 7.1 summarizes the characteristics of WHHLMi rabbits and their implementation in translational researches. LDL accumulates in the plasma due to LDL receptor deficiency, the low HDL-cholesterol and the metabolic syndrome-like

Characteristics of WHHLMI rabbits



Application for studies of diagnosis, therapeutics, and development of drugs for hypercholesterolemia, atherosclerosis, and other related diseases




Fig. 7.1 Characteristics of WHHLMI rabbits and the application

feature (accumulation of visceral fats and hyperinsulinemia) which cause the development of atherosclerotic lesions in aorta, coronary arteries, pulmonary arteries, carotid arteries, cerebral arteries and other arteries. Myocardial infarction occurs due to coronary occlusion by atherosclerotic lesions. In addition, xanthoma, overactive bladder and other diseases appeared related to hypercholesterolemia and atherosclerosis.

Ideally, it is essential that animal models should contribute not only to the mechanistic study of human diseases but also to the development of new drugs, devices, or techniques for therapeutics. As mentioned above, several hypocholesterolemic drugs have been developed and the anti-atherosclerotic effects of some of them could be proved. Statin is an inhibitor of HMG-CoA reductase, a rate-limiting enzyme in the cholesterol biosynthesis pathway. Lipid-lowering effect of statin was initially detected in WHHL rabbits and it is the most potent drugs to prevent acute coronary syndromes (Naghavi et al. 2003). Studies using WHHL rabbits contributed to understand how the reduction of the serum cholesterol levels stabilized atherosclerotic lesions (Shiomi et al. 1995). Recently, WHHLMI rabbits have been

used in studies based on imaging of atherosclerotic lesions by MRI (Meding et al. 2007; Steen et al. 2007), PET (Ogawa et al. 2006; Ishino et al. 2007) and intravascular ultrasound (IVUS) (Iwata et al. 2007). These techniques are promising for the identification of patients with coronary atherosclerosis to prevent acute coronary syndromes. In addition, WHHL (Kobe colony) and WHHLM rabbits also showed metabolic syndrome-like metabolic disorders, including the accumulation of visceral fats (Shiomi et al. 1999b), insulin resistance (Zhang et al. 1991; Shiomi et al. 1999b) and mildly hyperglycemia. Some WHHLM rabbits also showed overactive bladder and keratopathy (Garibaldi and Goad 1988).

7.3.3 Other Rabbit Models for Human Lipid Disorders

In 1987, La Ville et al. (La Ville et al. 1987) developed a rabbit strain characterized by hypercholesterolemia (394 ± 100 mg/dl) with moderately increased or normal triglyceride levels. This rabbit strain showed elevated endogenous lipoproteins (very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low-density lipoprotein (LDL)) cholesterol and LDL triglyceride levels due to over-secretion of VLDL from the liver. The LDL receptors functioned normally. Atherosclerosis developed in the aorta of these animals. These rabbits resemble human familial combined hyperlipidemia, which is one of the most common discrete hyperlipidemic disorders. Later on, this rabbit strain was bred into a new colony, the St. Thomas' mixed hyperlipidemic (SMHL) rabbit (Ardern et al. 1999). In SMHL rabbits, the serum cholesterol levels were 264 ± 68 mg/dl, and the triglyceride levels were 290 ± 55 mg/dl in feeding of very low cholesterol containing diet (0.08% cholesterol enriched diet) (De Roos et al. 2005). SMHL rabbits also showed insulin resistance (De Roos et al. 2001).

Ito and coworkers developed postprandial hypertriglyceridemic (PHT) rabbits (Kawai et al. 2006), which showed postprandial hypertriglyceridemia and metabolic syndrome-like feature. In PHT rabbits, the preprandial plasma triglyceride levels (4.55 ± 1.32 mmol/l) were about tenfold higher than in normal JW rabbits. After 15 h of continuously available feed of normal standard chow, the plasma triglyceride levels were markedly increased (15.9 ± 2.7 mmol/l) compared with the normal Japanese white rabbits (0.71 ± 0.01 mmol/l). In PHT rabbits, accumulation of visceral fat was prominent and insulin resistance was observed. These rabbits may also be important for the study of hyperlipidemia and metabolic syndrome.

7.4 Rabbit Models for Other Human Diseases

Rabbits also contributed to studies of cardiac function, infectious diseases, orthopedic surgery, cardiovascular surgery, and neoplastic diseases.

7.4.1 *Transgenic Rabbit Models for Prolonged QT and Sudden Cardiac Death in Human*

Recently, Brunner et al. (Brunner et al. 2008) reported that the expression of pore mutants of the human genes *KCNQ1* and *KCNH2* in rabbit hearts led to the generation of transgenic rabbits (LQT1 and LQT2) with a long QT phenotype. *KCNQ1* and *KCNH2* are genes encoding repolarizing K⁺ channels. The human long-QT syndrome is characterized by delayed ventricular repolarization, prolonged QT-interval, ventricular arrhythmia and sudden cardiac death. Current murine transgenic animal models of long-QT syndrome are limited by substantial differences in cardiac electrophysiology. LQT2 rabbits showed a high incidence of spontaneous sudden cardiac death (>50% at 1 year) due to polymorphic ventricular tachycardia. Optical mapping revealed increased spatial dispersion of repolarization underlying arrhythmia. These transgenic rabbits have been used as a model to detect the channel-blocking properties of some anesthetic agents (Odening et al. 2008). The transgenic LQT1 and LQT2 rabbits are thus suitable animal models for studying the human prolonged QT syndrome.

7.4.2 *Rabbit Models for Thrombogenesis*

An important event after plaque rupture is thrombogenesis. Development of thrombus under physiological conditions is rare in animal models. Recently, Yamashita et al (Yamashita et al. 2004) reported that a blood flow reduction after thrombus propagation related to arterial thrombogenicity in rabbit model after single and repeated balloon injuries. In their study, after balloon injury of the normal femoral artery of normal rabbits, the blood flow was reduced. As a result, increased vascular wall thrombogenicity together with a substantial blood flow reduction are crucial for occlusive thrombus formation and the von Willebrand factor plays an important role in thrombus propagation. Finally, they speculated that reduced blood flow at plaque disruption sites might contribute to thrombus propagation leading to acute coronary syndromes. In coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction, Hoshiba et al. (2006) observed co-localization of the von Willebrand factor with platelet thrombi, the tissue factor, platelets with fibrin and the consistent presence of inflammatory cells (CD16-positive neutrophils, CD45-positive mononuclear cells and CD34-positive blood progenitor cells). These studies suggest that, to propagate an arterial thrombus after a plaque rupture, a reduction of blood flow is important as well as the growing of the thrombus with inflammatory cells and erythrocytes. Therefore, rabbits are useful models for studies of thrombogenesis. Development of transgenic rabbits for factors of thrombogenesis may also play an important role.

7.4.3 Rabbit Models for Infectious Diseases and Deficiency of Immunological System

Manabe et al. (Manabe et al. 2008) showed that New Zealand white rabbits are useful animal for human latent tuberculosis. The global epidemic of tuberculosis claims more than two million lives yearly. *Mycobacterium tuberculosis* latently infects one third of the world population. They examined aerosol-infected rabbits with *Mycobacterium tuberculosis* and showed the formation of caseous lung granulomas which are strikingly similar to tuberculous lung lesions in humans. The lung burden of infection peaked at 5 weeks after aerosol infection followed by a host containment of infection that occurred in all rabbits. Corticosteroid-induced immunosuppression initiated after the disease containment resulted in a reactivation of disease. They also characterized the lung cellular immune response to inhaled *Mycobacterium tuberculosis* in the susceptible inbred Thorbecke rabbit (the genomically sequenced strain) and compared it to outbred, *Mycobacterium tuberculosis*-resistant, New Zealand white rabbits (Mendez et al. 2008). The development and severity of the immune reconstitution inflammatory syndrome was dependent on the antigen load at the time of immunosuppression and the subsequent bacillary replication during the corticosteroid-induced immunosuppression. This corticosteroid model is the only animal model to study the immune reconstitution inflammatory syndrome. The lung granulomas of inbred rabbits had a significantly higher number of cells expressing MHC Class II and CD11b, and a lower number of CD8 + T cells than the outbred controls. Effective utilization of this rabbit model could lead to a new tuberculosis diagnostic as well as to the elucidation of important correlates of protective immunity.

Human papillomavirus infections result in more than 250,000 deaths from cervical cancer in women worldwide. Hu et al. (2007) established a rabbit transgenic model expressing the human major histocompatibility complex (MHC-I) gene (HLA-A2.1). These transgenic rabbits expressed the HLA protein at a high level and HLA-A2.1 restricted rabbit CD8 cells were induced in these animals. Southern blot analysis demonstrated that the HLA-A2.1 gene was integrated into the rabbit genome and similar expression patterns of HLA-A2.1 and rabbit MHC class-I was observed in the three lines of transgenic rabbits. They demonstrated that HLA-A2.1 transgenic rabbits showed a susceptibility to cottontail rabbit papillomavirus infection akin to that of normal domestic rabbits. They also reported that a human papillomavirus type 16 E7 epitope can be engineered to be introduced into the cottontail rabbit papillomavirus E7 gene of the rabbit papillomavirus genome. This hybrid genome retained the ability to initiate papillomas. The cottontail rabbit papillomavirus/HLA-A2.1 rabbit model has the potential to be used to screen HLA-A2.1-restricted immunogenic epitopes from human papillomaviruses in the context of in vivo papillomavirus infection. These studies suggested that rabbit is an excellent model to assess both natural and induced immunity to papillomavirus infections and that the transgenic rabbits may have utility for assessment of immunity to other human pathogens that are permissive in rabbits.

Rother reported the existence of a mutant rabbit which was deficient in the sixth component of complement (Rother et al. 1966). Current studies based on the use of the 6 complement-deficient rabbits suggested that this component is involved in the activity of the immune system, the activation of the inflammatory response and the hemolytic activity. Chartrand et al. (1979) demonstrated that delayed rejection was observed in the puppy hearts engrafted to C6-deficient rabbits. Schmiedt et al. (1998) suggested that C6-deficient rabbits delayed the development of atherosclerosis by cholesterol feeding due to the weak inflammatory responses of arterial cells. Therefore, C6-deficient rabbits may contribute to study human diseases related to the immune system and the inflammatory responses.

7.4.4 Rabbit Models for Human Articular Lesions and Therapeutics

Patients with articular cartilage lesions caused by injury or degenerative joint diseases become increased recently and these defects do not repair spontaneously. Studies using rabbits have been contributed to tentatively develop therapeutics against the diseases. Ikeda et al. (2009) showed that rabbits are useful to examine the effect on porosity and of the mechanical properties of a synthetic polymer (DL-lactide-coglycolide) scaffold on repair of osteochondral defects. They treated rabbits suffering from osteochondral defects in the femoral condyle with three types of scaffolds. Their study suggested that higher porosity allowing bone marrow cells to migrate to the scaffold is important in repairing osteochondral defects. Nakayama et al. (2009) performed a mechanical analysis of the effects of fibroblast growth factor-2 (FGF-2) on autologous osteochondral transplantation in an artificial rabbit model. They induced a full-thickness cartilage defect in the right femoral condyle and treated with osteochondral transplantation using an osteochondral plug taken from the left femoral condyle. Autologous osteochondral grafts transplanted with gelatin hydrogel containing FGF-2 acquired adequate stiffness at early postoperative phase. In addition, Ishida et al. (2007) demonstrated that platelet-rich plasma enhances the healing of meniscal defects in rabbits. These studies demonstrate that rabbits are useful for studies to develop therapeutics about human articular lesions.

7.4.5 Rabbit Models for Vascular Surgery

Rabbits are also useful for studies to develop technique for vascular and respiratory surgery. Kawanishi et al. (2007) showed that the prevention of back-bleeding from intercostal arteries and lumbar arteries during thoracoabdominal aortic surgery was considered to reduce spinal ischemic injury. They examined the effects of back-bleeding in spinal cord by comparing rabbits without back-bleeding from

the lumbar arteries by draining from the aorta during aortic clamping with rabbits in which back-bleeding was not drained. Forty-eight hours later, the number of TUNEL-positive cells in rabbits draining back-bleeding was significantly smaller than those in rabbits with back-bleeding. Hasegawa et al. (2007) implanted autologous fibrin-coated vascular prostheses and/or xenologous fibrin-coated vascular prostheses in the bilateral carotid arteries of JW rabbits. As a result, autologous fibrin coating in thrombin-free fibrin-coated vascular prostheses improved antithrombogenicity. Their study suggested that autologous fibrin coating in thrombin-free fibrin-coated vascular prostheses have a potential for clinical use in hybrid small-caliber vascular grafts.

7.4.6 Rabbit Models for Tumor Study

Several transplantable rabbit tumors have been reported and VX2 tumor has been used in some studies. The VX2 carcinoma arose as the result of spontaneous transformation of a virus-induced skin papilloma in a domestic rabbit (Kidd and Rous 1940) and is a type of dermatological squamous cancer induced by the Shope virus. In general, the VX-2 tumor had a high malignant potential, with capacity for rapid reproduction, infiltration and metastasis. VX2 tumors have been transplanted into lung, liver, and other organs in rabbits. These rabbit VX2 tumors have been studied for establishing therapeutics and diagnostics. Virmani et al. (2008) demonstrated that hypoxia caused by transcatheter arterial embolization of VX2 liver tumors activates the hypoxia-inducible factor-1 alpha, a transcription factor that in turn regulates other pro-angiogenic factors. Jiang et al. (2008) reported that the hemodynamic changes in the liver caused by rabbit VX2 liver tumor can be detectable after tumor inoculation and that functional CT can evaluate the physiological characteristics of early angiogenesis. In addition, Ohira et al. (2008) demonstrated that EDG-PET was useful for monitoring the early effects of radiofrequency ablation in VX2 rabbit tumors implanted into the back muscles. These studies have demonstrated that rabbits are also useful for studies of tumor.

7.5 Conclusions

Genetically modified mice is playing an essential role in the clarification of the expression and functions of individual gene. However, to translate or extrapolate the results of animal studies to humans, it is necessary that key gene expression and function are equivalent to human rather than the outward features or phenotype. For example, to study human hypercholesterolemia, not only the hyperlipidemia itself, the characteristics of the lipoprotein profiles and enzymes in the lipoprotein metabolism of animal models is vitally important for translational researches. In addition, histopathological and/or immunohistochemical features similar to humans are

also important. Several rabbit models for some human diseases described in this chapter are useful in translational researches. Applying these animal models in translational researches will contribute to elucidation of the mechanism of human diseases and development of novel compounds, therapeutics, or diagnostic instruments containing lesion imaging techniques.

Acknowledgements This work was supported partly by a research grant from the Health and Labor Ministry of Japan and unrestricted research grants from Sankyo Co. Ltd., Japan.

References

- Anitschkow NN, Chalataw S (Translated by Pelias MZ). (1983) On experimental cholesterol steatosis and its significance in the origin of some pathological processes. *Arteriosclerosis* 3: 178–182. (The original article: Ueber experimentelle cholesterinsteatose und ihre bedeutung für die entstehung einiger pathologischer prozesse. *Zentralbl Allg Pathol Pathol Anat* 1913; 24: 1–9.)
- Ardern HA, Benson GM, Suckling KE, Caslake MJ, Shepherd J, Packard CJ. (1999) Apolipoprotein B overproduction by the perfused liver of the St. Thomas' mixed hyperlipidemic (SMHL) rabbit. *J Lipid Res* 40: 2234–2243.
- Brunner M, Peng X, Liu GX, Ren Z, Ziv O, Choi B, Mathur R, Hajjiri M, Odening KE, Steinberg E, Folco EJ, Pringa E, Centracchio J, Macharzina RR, Donahay T, Schofield L, Rana N, Kirk M, Mitchell GF, Poppas A, Zehender M, Koren G. (2008) Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome. *J Clin Invest* 118: 2246–2259.
- Chartrand C, O'Regan S, Robitaille P, Pino-Blonde M. (1979) Delayed rejection of cardiac xenografts in C6-deficient rabbits. *Immunology* 38: 245–248.
- Cybulsky MJ, Gimbrone MA. (1991) Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. *Science* 251: 788–791.
- De Roos B, Caslake MJ, Ardern HA, Benson GM, Suckling KE, Packard CJ. (2001) Insulin resistance in the St. Thomas' mixed hyperlipidemic (SMHL) rabbit, a model for familial combined hyperlipidemia. *Atherosclerosis* 156: 249–254.
- De Roos B, Caslake MJ, Milliner K, Benson GM, Suckling KE, Packard CJ. (2005) Characterisation of the lipoprotein structure in the St. Thomas' mixed hyperlipidemic (SMHL) rabbit. *Atherosclerosis* 181: 63–68.
- Fan J, Watanabe T. (2003) Transgenic rabbits as therapeutic protein bioreactors and human disease models. *Pharmacol Ther* 99: 261–282.
- Fleet JC, Clinton SK, Salomon RN, Loppnow H, Libby P. (1992) Atherogenic diets enhance endotoxin-stimulated interleukin-1 and tumor necrosis factor gene expression in rabbit aorta. *J Nutr* 122: 294–305.
- Galis ZS, Sukhova GK, Kränzhofer R, Clark S, Libby P. (1995) Macrophage foam cells from experimental atheroma constitutively produce matrix-degradation proteins. *Proc Natl Acad Sci USA* 92: 402–406.
- Garibaldi BA, Goad MEP. (1998) Lipid keratopathy in the Watanabe (WHHL) rabbit. *Vet Pathol* 25: 173–174.
- Goldstein JL, Kita T, Brown MS. (1983) Defective lipoprotein receptors and atherosclerosis: lessons from an animal counterpart of familial hypercholesterolemia. *N Engl J Med* 309: 288–296.
- Hasegawa T, Okada K, Takano Y, Hiraishi Y, Okita Y. (2007) Autologous fibrin-coated small-caliber vascular prostheses improve antithrombogenicity by reducing immunologic response. *J Thorac Cardiovasc Surg* 133: 1268–1276.

- Hoshiba Y, Hatakeyama K, Tanabe T, Asada Y, Goto S. (2006) Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. *J Thromb Haemost* 3: 1140–1120.
- Hu J, Peng X, Budgeon LR, Cladel NM, Balogh KK, Christensen ND. (2007) Establishment of a cottontail rabbit papillomavirus/HLA-A2.1 transgenic rabbit model. *J Virol* 81: 7171–7177.
- Ikeda R, Fujioka H, Nagura I, Kokubu T, Toyokawa N, Inui A, Makino T, Kaneko H, Doita M, Kurosaka M. (2009) The effects of porosity and mechanical property of a synthetic polymer scaffold on repair of osteochondral defects. *Int Orthop* (in press).
- Ishida K, Kuroda R, Miwa M, Tabata Y, Hokugo A, Kawamoto T, Sasaki K, Doita M, Kurosaka M. (2007) The regenerative effects of platelet-rich plasma on meniscal cells in vitro and its in vivo application with biodegradable gelatin hydrogel. *Tissue Eng* 13: 1103–1112.
- Ishino S, Mukai T, Kume N, Asano D, Ogawa M, Kuge Y, Minami M, Kita T, Shiomi M, Saji H. (2007) Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability-analysis in hypercholesterolemic rabbits. *Atherosclerosis* 195: 48–56.
- Ito T, Yamada S, Shiomi M. (2004) Progression of coronary atherosclerosis relates to the onset of myocardial infarction in an animal model of spontaneous myocardial infarction (WHHLMI rabbits). *Exp Anim* 53: 339–334.
- Iwata A, Miura S, Imaizumi B, Saku K. (2007) Measurement of atherosclerotic plaque volume in hyperlipidemic rabbit aorta by intravascular ultrasound. *J Cardiol* 50: 229–234.
- Jiang HJ, Zhang ZR, Shen BZ, Wan Y, Guo H, Shu SJ. (2008) Functional CT for assessment of early vascular physiology in liver tumors. *Hepatobiliary Pancreat Dis Int* 7: 497–502.
- Kawai T, Ito T, Ohwada K, Mera Y, Matsushita M, Tomoike H. (2006) Hereditary postprandial hypertriglyceridemic rabbit exhibits insulin resistance and central obesity: a novel model of metabolic syndrome. *Arterioscler Thromb Vasc Biol* 26: 2752–2757.
- Kawanishi Y, Okada K, Tanaka H, Yamashita T, Nakagiri K, Okita Y. (2007) The adverse effect of back-bleeding from lumbar arteries on spinal cord pathophysiology in a rabbit model. *J Thorac Cardiovasc Surg* 133: 1553–1558.
- Kidd JG, Rous P. (1940) A transplantable rabbit carcinoma originating in a virus-induced papilloma and containing the virus in masked or altered form. *J Exp Med* 71: 813–838.
- Kita T, Brown MS, Watanabe Y, Goldstein JL. (1981) Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia. *Proc Natl Acad Sci USA* 78: 2268–2272.
- Kozarsky KF, Bonen DK, Giannoni F, Funahashi T, Wilson JM, Davivson NO. (1996) Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apoBec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits. *Hum Gene Ther* 7: 973–977.
- La Ville A, Turner PR, Pittilo RM, Martini S, Marenah CB, Rowles PM, Morris G. (1987) Thomson GA, Woolf N, Lewis B. Hereditary hyperlipidemia in the rabbit due to overproduction of lipoproteins. I. Biochemical studies. *Arteriosclerosis* 7: 105–112.
- Manabe YC, Kesavan AK, Lopez-Molina J, Hatem CL, Brooks M, Fujiwara R, Hochstein K, Pitt MLM, Tufariello J, Chan J, McMurray DN, Bishai WR, Dannenberg AM, Mendez S. (2008) The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. *Tuberculosis* 88: 187–196.
- Mendez S, Hatem CL, Kesavan AK, Lopez-Molina J, Pitt ML, Dannenberg AM Jr, Manabe YC. (2008) Susceptibility to tuberculosis; composition of tuberculous granulomas in Thorbecke and outbred New Zealand white rabbits. *Vet Immunol Immunopathol* 122: 167–174.
- Meding J, Urich M, Licha K, Reinhardt M, Misselwitz B, Fayad ZA, Weimann HJ. (2007) Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M. *Contrast Media Mol Imag* 2: 120–129.
- Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Aikawa M, Airaksinen KEJ, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang I, Koenig W,

- Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, and Willerson JT. (2003) From vulnerable plaques to vulnerable patients, a call for new definitions and risk assessment strategies: Part I. *Circulation* 108: 1664–1672.
- Nakayama J, Fujioka H, Nagura I, Kokubu T, Makino T, Kuroda R, Tabata Y, Kurosaka M. (2009) The effect of fibroblast growth factor-2 on autologous osteochondral transplantation. *Int Orthop* 33: 275–280.
- Odening KE, Hyder O, Chaves L, Schofield L, Brunner M, Kirk M, Zehender M, Peng X, Koren G. (2008) Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization. *Am J Physiol Heart Circ Physiol* 295: H2264–H2272.
- Ogawa M, Magata Y, Kato T, Hatano K, Ishino S, Mukai T, Shiomi M, Ito K, Saji H. (2006) Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. *J Nucl Med* 47: 1845–1850.
- Ohira T, Okuma T, Matsuoka T, Wada Y, Nakamura K, Watanabe Y, Inoue Y. (2009) FDG-MicroPET and diffusion-weighted MR image evaluation of early changes after radiofrequency ablation in implanted VX2 tumors in rabbits. *Cardiovasc Intervent Radiol* 32: 114–120.
- Rosenfeld ME, Tsukada T, Gown AM, Ross R. (1987) Fatty streak initiation in Watanabe heritable hyperlipidemic and comparably hypercholesterolemic fat-fed rabbits. *Arteriosclerosis* 7: 9–23.
- Rosenfeld ME, Ylä-hertuala S, Lipton BA, Ord VA, Witztum JL, Steinberg D. (1992) Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. *Am J Pathol* 140: 291–300.
- Rother K, Rother U, Muller-Eberhard HJ, Nilsson UR. (1966) Deficiency of the sixth component of complement in rabbits with an inherited complement defect. *J Exp Med* 124: 773–785.
- Schmiedt W, Kinscherf R, Deigner HP, Kamencic H, Nauen O, Kilo J, Oelert H, Metz J, Bhakdi S. (1998) Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. *Arterioscler Thromb Vasc Biol* 18: 1790–1795.
- Shiomi M, Fan J. (2008) Unstable coronary plaques and cardiac events in myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits: questions and quandaries. *Curr Opin Lipidol* 19: 631–636.
- Shiomi M, Ito T. (1999a) Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. *Br J Pharmacol* 126: 961–968.
- Shiomi M, Ito T, Tsukada T, Tsujita Y, Horikoshi H. (1999b) Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows synergistic effect on atherosclerosis of WHHL rabbits. *Atherosclerosis* 142: 345–353.
- Shiomi M, Ito T, Tsukada T, Yata T, Ueda M. (1994) Cell compositions of coronary and aortic atherosclerotic lesions differ: An immunohistochemical study. *Arterioscler Thromb* 14: 931–937.
- Shiomi M, Ito T, Tsukada T, Yata T, Watanabe Y, Tsujita Y, Fukami M, Fukushige J, Hosokawa T, Tamura A. (1995) Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. *Arterioscler Thromb Vasc Biol* 15: 1938–1944.
- Shiomi M, Ito T, Yamada S, Kawashima S, Fan J. (2003) Development of an animal model for spontaneous myocardial infarction (WHHLMI Rabbit). *Arterioscler Thromb Vasc Biol* 23: 1239–1244.
- Shiomi M, Yamada S, Ito T. (2005) Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary atherosclerosis-prone WHHL rabbits. *Atherosclerosis* 178: 287–294.
- Son YC, Zilverman DB. (1986) Increased lipid transfer activities in hyperlipidemic rabbit plasma. *Arteriosclerosis* 6: 345–351.

- Steen H, Lima JA, Chatterjee S, Kolmakova A, Gao F, Rodrigues ER, Stuber M. (2007) High-resolution three-dimensional aortic magnetic resonance angiography and quantitative vessel wall characterization of different atherosclerotic stages in a rabbit model. *Invest Radiol* 42: 614–621.
- Tanzawa K, Shimada Y, Kuroda M, Tsujita Y, Arai M, Watanabe Y. (1980) WHHL-rabbit: a low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia. *FEBS Lett* 118: 81–84.
- Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M, Masuda H, Tarumi C, Watanabe Y, Fujii S. (1986) CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. *Biochim Biophys Acta* 877: 50–60.
- Virmani S, Rhee TK, Ryu RK, Sato KT, Lewandowski RJ, Mulcahy MF, Kulik LM, Szolc-Kowalska B, Woloschak GE, Yang GY, Salem R, Larsin AC, Omary RA. (2008) Comparison of hypoxia-inducible factor-1 α expression before and after transcatheter arterial embolisation in rabbit VX2 liver tumors. *J Vasc Interv Radiol* 19: 1483–1489.
- Watanabe Y. (1980) Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). *Atherosclerosis* 36: 261–268.
- Watanabe Y, Ito T, Saeki M, Kuroda M, Tanzawa K, Mochizuki M, Tsujita Y, Arai M. (1981) Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia. *Atherosclerosis* 38: 27–31.
- Watanabe Y, Ito T, Shiomi M. (1985) The effect of selective breeding on the development of coronary atherosclerosis. *Atherosclerosis* 56: 71–79.
- Watanabe Y, Ito T, Shiomi M, Tsujita Y, Kuroda M, Arai M, Fukami M, Tamura A. (1988) Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. *Biochim Biophys Acta* 960: 294–302.
- Yamamoto T, Bishop RW, Brown MS, Goldstein JL, Russell DW. (1986) Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. *Science* 232: 1230–1237.
- Yamashita A, Furukoli E, Marutsuka K, Hatakeyama K, Yamamoto H, Tamura S, Ikeda Y, Sumiyoshi A, Asada Y. (2004) Increased vascular wall thrombogenicity combined with reduced blood flow promotes occlusive thrombus formation in rabbit femoral artery. *Arterioscler Thromb Vasc Biol* 24: 2420–2424.
- Ylä-Herrttuala S, Lipton BA, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. (1991) Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. *Proc Natl Acad Sci USA* 88: 5252–5256.
- Zhang B, Saku K, Hirata K, Liu R. (1991) Tateishi K, Yamamoto K, Arakawa K. Insulin resistance observed in WHHL rabbits. *Atherosclerosis* 91: 277–278.